All In Biotech

Drug Trial Radar · NCT05956587

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

121

Planned (sponsor's estimate)

Start

Jan 29, 2024

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Jul 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and mode of combination.

Conditions

  • Non-small Cell Lung Cancer
  • Nasopharyngeal Carcinoma

Interventions

  • BL-B01D1Drug

    Administration by intravenous infusion

  • SI-B003Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to approximately 24 months
  2. Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospita

    Changsha, Hunan, China · Not yet recruiting

  • The Second Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Linyi Cancer Hospital

    Linyi, Shangdong, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.